| Index | — | P/E | 18.18 | EPS (ttm) | 0.76 | Insider Own | 1.50% | Shs Outstand | 262.61M | Perf Week | 0.73% |
| Market Cap | 3.63B | Forward P/E | 3.81 | EPS next Y | 3.63 | Insider Trans | -0.37% | Shs Float | 260.93M | Perf Month | 1.09% |
| Enterprise Value | 10.73B | PEG | 4.70 | EPS next Q | 0.92 | Short Float | 7.21% | Perf Quarter | 2.06% | ||
| Income | 213.00M | P/S | 0.60 | EPS this Y | -10.76% | Short Ratio | 7.07 | Perf Half Y | 3.75% | ||
| Sales | 6.10B | P/B | 3.04 | EPS next Y | 8.36% | ROA | 1.59% | Short Interest | 18.82M | Perf YTD | 93.17% |
| Book/sh | 4.54 | P/C | 2.49 | EPS next 5Y | 3.87% | ROE | 22.11% | 52W High | 13.85 0.00% | Perf Year | 105.19% |
| Cash/sh | 5.54 | P/FCF | 5.38 | EPS past 3/5Y | -41.47% -38.99% | ROIC | 4.65% | 52W Low | 5.69 143.41% | Perf 3Y | -7.42% |
| Dividend Est. | 0.08 (0.58%) | EV/EBITDA | 8.30 | Sales past 3/5Y | 0.23% -0.99% | Gross Margin | 53.42% | Volatility | 0.26% 0.28% | Perf 5Y | -62.27% |
| Dividend TTM | 0.08 (0.58%) | EV/Sales | 1.76 | EPS Y/Y TTM | -60.42% | Oper. Margin | 19.50% | ATR (14) | 0.04 | Perf 10Y | — |
| Dividend Ex-Date | Nov 09, 2026 | Quick Ratio | 1.51 | Sales Y/Y TTM | -3.21% | Profit Margin | 3.49% | RSI (14) | 66.71 | Recom | 3.11 |
| Dividend Gr. 3/5Y | -32.79% — | Current Ratio | 2.02 | EPS Q/Q | -6.93% | SMA20 | 0.54% | Beta | 1.47 | Target Price | 11.00 |
| Payout | 9.39% | Debt/Eq | 7.17 | Sales Q/Q | -1.75% | SMA50 | 0.80% | Rel Volume | 1.40 | Prev Close | 13.82 |
| Employees | 10,000 | LT Debt/Eq | 7.11 | Earnings | Feb 11 | SMA200 | 19.72% | Avg Volume | 2.62M | Price | 13.85 |
| IPO Date | May 14, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 6.82% -0.11% | Net Debt/EBITDA | 5.49 | Volume | 3,657,863 | Change | 0.22% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Apr-29-26 | Downgrade | BNP Paribas | Outperform → Neutral | |
| Apr-28-26 | Upgrade | Piper Sandler | Underweight → Neutral | $14 |
| Apr-10-26 | Reiterated | BNP Paribas | $12 | |
| Feb-24-26 | Reiterated | Barclays | Underweight | $7.50 → $8.00 |
| Dec-08-25 | Initiated | Barclays | Underweight | $7.50 |
| Oct-27-25 | Reiterated | Piper Sandler | Overweight | $18 → $5.00 |
| May-15-25 | Reiterated | Piper Sandler | Overweight | $24 → $18 |
| May-05-25 | Reiterated | Morgan Stanley | Equal Weight | $10 |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight | |
| Apr-29-24 | Reiterated | Piper Sandler | Overweight | $34 → $24 |
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 6,099 | 6,216 | 6,403 | 6,263 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,841 | 2,854 | 2,688 | 2,515 | — | — | — | — | — | |
| Gross Profit | 3,258 | 3,362 | 3,715 | 3,748 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,712 | 1,711 | 1,760 | 1,893 | — | — | — | — | — | |
| Research and Development | 357 | 366 | 469 | 528 | — | — | — | — | — | |
| Other Operating Expense | 0 | 10 | 0 | 0 | — | — | — | — | — | |
| Operating Income | 1,189 | 1,285 | 1,486 | 1,327 | — | — | — | — | — | |
| Interest Expense | 446 | 504 | 520 | 527 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -240 | -356 | -159 | -127 | — | — | — | — | — | |
| Net Income Before Taxes | 503 | 425 | 807 | 673 | — | — | — | — | — | |
| Income Taxes | 290 | 238 | -57 | -350 | — | — | — | — | — | |
| Consolidated Net Income | 213 | 187 | 864 | 1,023 | — | — | — | — | — | |
| Net Income From Continuing Operations | 213 | 187 | 864 | 1,023 | — | — | — | — | — | |
| Net Income | 213 | 187 | 864 | 1,023 | — | — | — | — | — | |
| EPS (Recurring) | 0.79 | 0.72 | 3.36 | 4.01 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.79 | 0.72 | 3.36 | 4.01 | — | — | — | — | — | |
| EPS (Diluted) | 0.76 | 0.72 | 3.33 | 3.99 | — | — | — | — | — | |
| EBITDA | 1,293 | 1,290 | 1,604 | 1,436 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 18.22 | 9.96 | 4.48 | 3.61 | — | — | — | — | — | |
| Price To Sales Ratio | 0.60 | 0.30 | 0.60 | 0.59 | — | — | — | — | — | |
| Gross Margin | 53.42 | 54.09 | 58.02 | 59.84 | — | — | — | — | — | |
| Operating Margin | 19.49 | 20.67 | 23.21 | 21.19 | — | — | — | — | — | |
| Net Margin | 3.49 | 3.01 | 13.49 | 16.33 | — | — | — | — | — | |
| Shares Outstanding | 263 | 259 | 257 | 255 | — | — | — | — | — | |
| Market Capitalization | 3,643 | 1,857 | 3,834 | 3,677 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Arjona Ferreira Juan Camilo | Head of R&D & CMO | Aug 11 '26 | Option Exercise | 0.00 | 23,038 | 0 | 41,566 | Aug 12 |
| Drinane Juliana Papa | Head of Mfg & Supply | Aug 05 '26 | Sale | 13.57 | 14,761 | 200,307 | 18,475 | Aug 05 |
| Holzbaur Lynette | SVP and Corporate Controller | May 06 '26 | Sale | 13.35 | 26,448 | 353,080 | 0 | May 07 |
| Holzbaur Lynette | SVP and Corporate Controller | May 06 '26 | Buy | 13.35 | 26,448 | 353,080 | 52,851 | May 07 |
| Stahler Rachel A | Chief Information Officer | Mar 31 '26 | Option Exercise | 0.00 | 18,867 | 0 | 120,322 | Apr 02 |
| WALSH MATTHEW M | Chief Financial Officer | Mar 31 '26 | Option Exercise | 0.00 | 33,593 | 0 | 220,126 | Apr 02 |
| Falcione Aaron | Chief Human Resources Officer | Mar 31 '26 | Option Exercise | 0.00 | 17,925 | 0 | 105,265 | Apr 02 |
| Weaver Kirke | Gen. Counsel & Corp. Secy. | Mar 31 '26 | Option Exercise | 0.00 | 18,513 | 0 | 96,147 | Apr 02 |
| Nisita Vittorio | Head of Global Business Svcs | Mar 31 '26 | Option Exercise | 0.00 | 13,000 | 0 | 73,494 | Apr 02 |
| Holzbaur Lynette | SVP and Corporate Controller | Mar 31 '26 | Option Exercise | 0.00 | 10,967 | 0 | 28,316 | Apr 02 |
| Morrissey Joseph T. Jr. | Interim CEO | Mar 31 '26 | Option Exercise | 0.00 | 24,584 | 0 | 127,907 | Apr 02 |
| Drinane Juliana Papa | Interim Head of Mfg & Supply | Mar 31 '26 | Option Exercise | 0.00 | 16,451 | 0 | 36,687 | Apr 02 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO | Mar 31 '26 | Option Exercise | 0.00 | 13,431 | 0 | 34,867 | Apr 02 |
| Karp Daniel | Executive VP, Corp. Dev. | Mar 31 '26 | Option Exercise | 0.00 | 18,053 | 0 | 71,653 | Apr 02 |
| Stahler Rachel A | Chief Information Officer | Mar 29 '26 | Option Exercise | 0.00 | 8,200 | 0 | 106,510 | Mar 31 |